| Literature DB >> 27088710 |
Amélie Rollé, Kinda Schepers, Sylvie Cassadou, Elodie Curlier, Benjamin Madeux, Cécile Hermann-Storck, Isabelle Fabre, Isabelle Lamaury, Benoit Tressières, Guillaume Thiery, Bruno Hoen.
Abstract
During a 2014 outbreak, 450 patients with confirmed chikungunya virus infection were admitted to the University Hospital of Pointe-à-Pitre, Guadeloupe. Of these, 110 were nonpregnant adults; 42 had severe disease, and of those, 25 had severe sepsis or septic shock and 12 died. Severe sepsis may be a rare complication of chikungunya virus infection.Entities:
Keywords: CHIKV; French West Indies; Guadeloupe; chikungunya; septic shock; severe sepsis; vector-borne infections; viruses
Mesh:
Year: 2016 PMID: 27088710 PMCID: PMC4861514 DOI: 10.3201/eid2205.151449
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Selected characteristics of 110 nonpregnant adult patients with chikungunya virus infection, by severity of disease, University Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, January–November 2014*
| Characteristic | Nonsevere, n = 68 | Severe, n = 42 | p value† |
|---|---|---|---|
| Baseline characteristics | |||
| Median age, y (interquartile range) | 71 (59–80) | 68 (58–77) | 0.27 |
| Male sex | 36 (53) | 26 (62) | 0.36 |
| Preexisting comorbid conditions | |||
| Immune suppression | 4 (6) | 1 (2) | 0.69 |
| Diabetes mellitus | 28 (41) | 16 (38) | 0.75 |
| Chronic heart disease | 9 (14) | 11 (28) | 0.07 |
| Cerebrovascular disease | 6 (9) | 1 (3) | 0.35 |
| Chronic lung disease | 1 (2) | 2 (5) | 0.66 |
| Chronic liver disease | 0 | 1 (3) | 0.8 |
| Chronic renal disease | 5 (8) | 4 (10) | 0.95 |
| Cancer | 5 (8) | 2 (5) | 0.92 |
| Charlson index, median (interquartile range) | 4 (3–5) | 4 (1–5) | 0,41 |
| McCabe class 1 | 50 (77) | 24 (62) | 0.09 |
| Clinical symptoms, present on admission to hospital | |||
| Arthralgia/arthritis | 49 (82) | 30 (83) | 0.84 |
| Headache | 21 (39) | 3 (9) | 0,002 |
| Fever | 61 (92) | 35 (83) | 0.25 |
| Myalgia | 24 (48) | 13 (41) | 0.41 |
| Cardiac manifestations | 10 (15) | 28 (67) | <0.001 |
| Central nervous system manifestations | 20 (30) | 13 (31) | <0.001 |
| Respiratory manifestations | 9 (14) | 29 (71) | <0.001 |
| Hepatic manifestations | 1 (2) | 12 (29) | <0.001 |
| Renal manifestations | 12 (19) | 20 (50) | 0.001 |
| Organ failures, at any time of the course of the disease | |||
| Cardio-circulatory failure | 0 | 22 (52) | <0.001 |
| Neurologic failure | 0 | 6 (14) | 0.006 |
| Respiratory failure | 0 | 21 (50) | <0.001 |
| Liver failure | 0 | 9 (21) | <0.001 |
| Renal failure | 0 | 15 (36) | <0.001 |
| Laboratory data, median (interquartile range) | |||
| Whole leukocytes, day 1, G/L | 5.80 (4.00–7.00) | 7.50 (4.90–13.00) | 0.01 |
| Whole leukocytes, days 2–7, G/L | 3.00 (2.10–5.40) | 8.70 (3.20–14.70) | <0.001 |
| Polymorphonuclear neutrophils, day 1, G/L | 4.16 (2.82–5.43) | 5.59 (3.40–10.94) | 0.01 |
| Polymorphonuclear neutrophils, days 2–7, G/L | 1.63 (1.05–5.02) | 7.13 (2.32–11.82) | <0.001 |
| Hemoglobin, day 1, g/dL | 12.6 (11.3–13.6) | 12.1 (10.2–13.5) | 0.25 |
| Hemoglobin, days 2–7, g/dL | 11.9 (11.3–13.6) | 8.6 (10.5–11.6) | <0.001 |
| Platelets, day 1, G/L | 178(125–233) | 147 (107–199) | 0.13 |
| Platelets, days 2–7, G/L | 160 (110–200) | 108 (75–189) | 0.04 |
| C-reactive protein, day 1, mg/L | 36 (20–79) | 43 (16–75) | 0.57 |
| C-reactive protein, days 2–7, mg/L | 70 (33–106) | 94 (37–167) | 0.24 |
| Lactate dehydrogenase, day 1, IU/L | 286 (207–354) | 579 (310–1135) | 0.001 |
| Lactate dehydrogenase, days 2–7, IU/L | 363 (248–418) | 422 (335–1600) | 0.04 |
| Creatine kinase, day 1, IU/L | 268 (132–808) | 395 (237–740) | 0.36 |
| Creatine kinase, day 2, IU/L | 973 (163–2826) | 683 (240–2164) | 0.85 |
| Aspartate aminotransferase, day 1, IU/L | 34 (25–48) | 50 (30–127) | 0.01 |
| Aspartate aminotransferase, days 2–7, IU/L | 28 (19–58) | 64 (33–351) | 0.2 |
| Alanine aminotransferase, day 1, IU/L | 20 (15–30) | 31 (21–57) | 0.02 |
| Alanine aminotransferase, days 2–7, IU/L | 28 (19–58) | 40 (20–234) | 0.1 |
| Creatinine, day 1, µmol/L | 95 (78–131) | 119 (81–182) | 0.07 |
| Creatinine, days 2–7, µmol/L | 101 (81–139) | 153 (75–410) | 0.09 |
| Outcome | |||
| Death | 1 (2) | 13 (31) | <0.001 |
*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR. †p value denotes the comparisons between the 42 patients with severe forms and the 68 patients with nonsevere forms, based on nonparametrical tests.
Selected characteristics of 110 nonpregnant adult patients with chikungunya virus infection, by presence or absence of sepsis or septic shock, University Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, January–November 2014*
| Characteristic | Severe sepsis or septic shock, n = 25 | No severe sepsis or septic shock, n = 85 | p value† |
|---|---|---|---|
| Baseline characteristics | |||
| Median age, y (interquartile range) | 70 (59–77) | 70 (59–78) | 0.966 |
| Male sex | 17 (68) | 45 (53) | 0.252 |
| Preexisting comorbid conditions | |||
| Immune suppression | 1 (4) | 4 (5) | 1 |
| Diabetes mellitus | 10 (40) | 34 (40) | 1 |
| Chronic heart disease | 6 (26) | 14 (17) | 0.374 |
| Cerebrovascular disease | 1 (4) | 6 (8) | 1 |
| Chronic lung disease | 2 (9) | 1 (1) | 0.124 |
| Chronic liver disease | 1 (4) | 0 (0) | 0.223 |
| Chronic renal disease | 3 (13) | 6 (8) | 0.414 |
| Cancer | 1 (4) | 6 (7) | 1 |
| Charlson index, median (interquartile range) | 4 (3–5) | 4 (2–5) | 0.579 |
| McCabe class 1 | 9 (39) | 21 (26) | 0.296 |
| Clinical symptoms, present on admission to hospital | |||
| Arthralgia/arthritis | 19 (91) | 60 (80) | 0.347 |
| Headache | 3 (17) | 21 (30) | 0.376 |
| Fever | 21 (84) | 75 (90) | 0.467 |
| Myalgia | 8 (44) | 29 (45) | 1 |
| Cardiac manifestations | 20 (80) | 18 (22) | <0.001 |
| Central nervous system manifestations | 8 (32) | 25 (30) | 1 |
| Respiratory manifestations | 18 (72) | 20 (24) | <0.001 |
| Hepatic manifestations | 7 (28) | 6 (8) | 0.012 |
| Renal manifestations | 17 (71) | 15 (19) | <0.001 |
| Organ failures, at any time of the course of the disease | |||
| Cardio-circulatory failure | 17 (68) | 5 (6) | <0.001 |
| Neurologic failure | 3 (12) | 3 (4) | 0.129 |
| Respiratory failure | 14 (56) | 7 (8) | <0.001 |
| Liver failure | 6 (24) | 3 (4) | 0.004 |
| Renal failure | 13 (52) | 2 (2) | <0.001 |
| Laboratory data, median (interquartile range) | |||
| Whole leukocytes, day 1, G/L | 8.10 (6.10–13.10) | 5.80 (4.10–7.10) | 0.004 |
| Whole leukocytes, days 2–7, G/L | 10.70 (3.40–15.00) | 3.05 (2.35–7.00) | <0.001 |
| Polymorphonuclear neutrophils, day 1, G/L | 5.96 (4.48–11.02) | 4.30 (2.82–5.91) | 0.01 |
| Polymorphonuclear neutrophils, days 2–7, G/L | 8.73 (2.55–12.02) | 1.80 (1.09–5.86) | <0.001 |
| Hemoglobin, day 1, g/dL | 12.1 (10.6–13.5) | 12.5 (11.2–13.5) | 0.796 |
| Hemoglobin, days 2–7, g/dL | 10.6 (7.9–11.7) | 11.7 (10.3–12.9) | 0.013 |
| Platelets, day 1, G/L | 139 (106–192) | 176 (123–233) | 0.063 |
| Platelets, days 2–7, G/L | 104 (59–189) | 149 (108–200) | 0.03 |
| C-reactive protein, day 1, mg/L | 46 (20–75) | 40 (20–79) | 0.856 |
| C-reactive protein, days 2–7, mg/L | 92 (41–204) | 70 (33–106) | 0.119 |
| Lactate dehydrogenase, day 1, IU/L | 606 (288–946) | 310 (226–401) | 0.007 |
| Lactate dehydrogenase, days 2–7, IU/L | 422 (346–1600) | 363 (266–422) | 0.05 |
| Creatine kinase, day 1, IU/L | 653 (304–1394) | 264 (140–639) | 0.08 |
| Creatine kinase, day 2, IU/L | 911 (357–3932) | 727 (163–2642) | 0.283 |
| Aspartate aminotransferase, day 1, IU/L | 60 (39–127) | 33 (24–48) | 0.001 |
| Aspartate aminotransferase, days 2–7, IU/L | 125 (36–626) | 54 (35–104) | 0.044 |
| Alanine aminotransferase, day 1, IU/L | 33 (24–57) | 20 (15–31) | 0.02 |
| Alanine aminotransferase, days 2–7, IU/L | 56 (28–499) | 30 (19–61) | 0.055 |
| Creatinine, day 1, µmol/L | 157 (114–343) | 96 (77–134) | 0.008 |
| Creatinine, days 2–7, µmol/L | 226 (123–570) | 101 (76–141) | 0.002 |
| Outcome | |||
| Death | 12 (48) | 2 (3) | <0.001 |
*Values are no. (%) except as indicated. All patients were hospitalized and had infection confirmed by reverse transcription PCR. †p value denotes the comparisons between the 25 patients with severe sepsis or septic shock and the 85 patients with no severe sepsis or septic shock, based on nonparametrical tests.